Is Illumina a victim of its own success? What makes the FDA change its mind? And how will petrodollars change biotech?
We cover all that and more this week on “The Readout LOUD,” STAT’s biotech podcast. Our colleague Matthew Herper joins us to discuss how Illumina, the biggest company in genomic sequencing, got into an $8 billion predicament. We also discuss a dramatic development for a new ALS treatment, the latest in cancer research, and a well-funded new player in biotech venture capital.
Also — if you had some technical difficulties loading the episode on Apple Podcasts, try again. We fixed it!
mRNA became mainstream with Covid vaccines. But the technology’s therapeutic potential is huge.
mRNA has proven itself in Covid-19 vaccines. But that’s just the beginning. How can we use mRNA to take health care to the next level — to potentially cure neurological disorders and the deadliest of cancers? While scientists explore those questions, biopharma must make some adjustments to pave the road to success. Read the article here.
No comments